A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...